{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:03:03Z","timestamp":1787169783372,"version":"build-2736575974"},"reference-count":232,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000046","name":"National Research Council Canada","doi-asserted-by":"publisher","award":["53804"],"award-info":[{"award-number":["53804"]}],"id":[{"id":"10.13039\/501100000046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.034","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T04:51:10Z","timestamp":1710823870000},"page":"2530-2542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["CHO cells for virus-like particle and subunit vaccine manufacturing"],"prefix":"10.1016","volume":"42","author":[{"given":"Zalma V.","family":"Sanchez-Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio P.","family":"Alpuche-Lazcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Stuible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2268-4111","authenticated-orcid":false,"given":"Yves","family":"Durocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.034_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168113","article-title":"Historical advances in structural and molecular biology and how they impacted vaccine development","volume":"435","author":"Koff","year":"2023","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0010","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/biot.201400387","article-title":"Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology","volume":"10","author":"Rodrigues","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2024.03.034_b0015","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41587-022-01582-x","article-title":"Biopharmaceutical benchmarks 2022","volume":"40","author":"Walsh","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0020","unstructured":"U.S. Food and Drug Administration. SHINGRIX. (2017). https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/shingrix. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0025","unstructured":"U.S. Food and Drug Administration. PREHEVBRIO. (2021). https:\/\/www.fda.gov\/vaccines-blood-biologics\/prehevbrio. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0030","unstructured":"AREXVY | U.S. Food and Drug Administration. (2023). https:\/\/www.fda.gov\/vaccines-blood-biologics\/arexvy. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0035","unstructured":"U.S. Food and Drug Administration. ABRYSVO. (2023). https:\/\/www.fda.gov\/vaccines-blood-biologics\/abrysvo. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0040","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1084\/jem.108.6.945","article-title":"Genetics of somatic mammalian cells. III. Long-term cultivation of euploid cells from human and animal subjects","volume":"108","author":"Puck","year":"1958","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ddtec.2021.02.003","article-title":"Recent advances in CHO cell line development for recombinant protein production","volume":"38","author":"Tihanyi","year":"2020","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.febslet.2004.11.027","article-title":"Structural basis of eukaryotic gene transcription","volume":"579","author":"Boeger","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2024.03.034_b0055","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jbiotec.2017.04.028","article-title":"Therapeutic glycoprotein production in mammalian cells","volume":"251","author":"Lalonde","year":"2017","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0060","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nbt.1932","article-title":"The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line","volume":"29","author":"Xu","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0065","first-page":"2524","article-title":"Model-driven engineering of N-linked glycosylation in Chinese hamster ovary cells","volume":"8","author":"Stach","year":"2019","journal-title":"ACS syn bio [electronic resource]"},{"key":"10.1016\/j.vaccine.2024.03.034_b0070","doi-asserted-by":"crossref","first-page":"1700234","DOI":"10.1002\/biot.201700234","article-title":"Glycoengineering in CHO cells: advances in systems biology","volume":"13","author":"Tejwani","year":"2018","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2024.03.034_b0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0076-6879(06)16011-5","article-title":"Lectin-resistant CHO glycosylation mutants","volume":"416","author":"Patnaik","year":"2006","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0080","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/bit.28127","article-title":"Production of afucosylated antibodies in CHO cells by coexpression of an anti-FUT8 intrabody","volume":"119","author":"Joubert","year":"2022","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2024.03.034_b0085","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/bit.28129","article-title":"High-level production of wild-type and oxidation-resistant recombinant alpha-1-antitrypsin in glycoengineered CHO cells","volume":"119","author":"Koyuturk","year":"2022","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2024.03.034_b0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-4939-6972-2_2","article-title":"Glycoengineering of CHO cells to improve product quality","volume":"1603","author":"Wang","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0095","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.copbio.2019.01.011","article-title":"The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem","volume":"60","author":"Dahodwala","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0100","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/btpr.2706","article-title":"Cell culture media for recombinant protein expression in Chinese hamster ovary (CHO) cells: History, key components, and optimization strategies","volume":"34","author":"Ritacco","year":"2018","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.vaccine.2024.03.034_b0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.febslet.2013.11.035","article-title":"Recent advances in mammalian protein production","volume":"588","author":"Bandaranayake","year":"2014","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2024.03.034_b0110","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/07388551.2017.1419459","article-title":"Advancements in mammalian cell transient gene expression (TGE) technology for accelerated production of biologics","volume":"38","author":"Guti\u00e9rrez-Granados","year":"2018","journal-title":"Crit Rev Biotechnol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/1087057114563494","article-title":"CHO-S antibody titers >1 gram\/liter using flow electroporation-mediated transient gene expression followed by rapid migration to high-yield stable cell lines","volume":"20","author":"Steger","year":"2015","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.vaccine.2024.03.034_b0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.coche.2018.09.010","article-title":"Beyond preclinical research: production of CHO-derived biotherapeutics for toxicology and early-phase trials by transient gene expression or stable pools","volume":"22","author":"Stuible","year":"2018","journal-title":"Curr Opin Chem Eng"},{"key":"10.1016\/j.vaccine.2024.03.034_b0125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10295-013-1235-0","article-title":"Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells","volume":"40","author":"Berlec","year":"2013","journal-title":"J Ind Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0130","unstructured":"Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks, Annex 3, TRS No 978."},{"key":"10.1016\/j.vaccine.2024.03.034_b0135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.biologicals.2019.09.006","article-title":"Considering \u201cclonality\u201d: A regulatory perspective on the importance of the clonal derivation of mammalian cell banks in biopharmaceutical development","volume":"62","author":"Welch","year":"2019","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2024.03.034_b0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pervac.2011.05.003","article-title":"Vaccine antigens","volume":"1","author":"Strugnell","year":"2011","journal-title":"Perspect Vaccinol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0145","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0150","unstructured":"U.S. Food and Drug Administration. Novavax COVID-19 Vaccine, Adjuvanted. (2023). https:\/\/www.fda.gov\/vaccines-blood-biologics\/coronavirus-covid-19-cber-regulated-biologics\/novavax-covid-19-vaccine-adjuvanted. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0155","unstructured":"European Medicines Agency. Shingrix. (2018). [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0160","unstructured":"U.S. Food and Drug Administration. Flublok. (2013). https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/flublok. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0165","unstructured":"U.S. Food and Drug Administration. Flublok Quadrivalent. (2016). https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/flublok-quadrivalent. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0170","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1016\/j.apsb.2023.01.006","article-title":"Advanced subunit vaccine delivery technologies: from vaccine cascade obstacles to design strategies","volume":"13","author":"Hou","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.vaccine.2024.03.034_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2024.03.034_b0180","article-title":"Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 protein vaccine","author":"Dayan","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2024.03.034_b0185","series-title":"Bioprocessing of viral vaccines","first-page":"35","article-title":"Introduction to basic immunology and vaccine design","author":"Mullick","year":"2023"},{"key":"10.1016\/j.vaccine.2024.03.034_b0190","series-title":"Virus-like particles: a comprehensive guide","author":"Pumpens","year":"2022"},{"key":"10.1016\/j.vaccine.2024.03.034_b0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","article-title":"Construction and characterization of virus-like particles: a review","volume":"53","author":"Zeltins","year":"2013","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0200","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/jvi.65.6.2946-2952.1991","article-title":"Expression of rotavirus VP2 produces empty corelike particles","volume":"65","author":"Labb\u00e9","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0205","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0042-6822(95)80027-1","article-title":"Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe","volume":"206","author":"Sasagawa","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.03.034_b0210","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1472-6750-11-106","article-title":"Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants","volume":"11","author":"Mati\u0107","year":"2011","journal-title":"BMC Biotech"},{"key":"10.1016\/j.vaccine.2024.03.034_b0215","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1016\/j.vaccine.2009.06.045","article-title":"Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice","volume":"27","author":"Lico","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0220","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/bit.25159","article-title":"Bioengineering virus-like particles as vaccines","volume":"111","author":"Lua","year":"2014","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2024.03.034_b0225","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0264-410X(93)90316-P","article-title":"Recombinant-expressed virus-like particle pseudotypes as an approach to vaccine development","volume":"11","author":"McGuigan","year":"1993","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0230","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14760584.2020.1738227","article-title":"Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines","volume":"19","author":"Lei","year":"2020","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.vaccine.2024.03.034_b0235","doi-asserted-by":"crossref","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","article-title":"Advances and challenges in enveloped virus-like particle (VLP)-based vaccines","volume":"2","author":"Deng","year":"2018","journal-title":"J immunol sci"},{"key":"10.1016\/j.vaccine.2024.03.034_b0240","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jbiotec.2013.05.001","article-title":"Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium","volume":"166","author":"Cervera","year":"2013","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0245","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pep.2013.05.009","article-title":"Use of baculovirus expression system for generation of virus-like particles: successes and challenges","volume":"90","author":"Liu","year":"2013","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2024.03.034_b0250","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b0255","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3389\/fimmu.2020.01100","article-title":"Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): toward better engineering of VLPs","volume":"11","author":"Zepeda-Cervantes","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0260","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2024.03.034_b0265","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/14760584.6.3.381","article-title":"Virus-like particles: flexible platforms for vaccine development","volume":"6","author":"Chackerian","year":"2007","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.vaccine.2024.03.034_b0270","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/eji.1830261109","article-title":"Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes","volume":"26","author":"Bachmann","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0275","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/jphp.12353","article-title":"Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?","volume":"67","author":"Bill","year":"2015","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0280","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fmicb.2014.00085","article-title":"Playing catch-up with Escherichia coli: using yeast to increase success rates in recombinant protein production experiments","volume":"5","author":"Bill","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1475-2859-9-27","article-title":"Towards universal systems for recombinant gene expression","volume":"9","author":"S\u00f8rensen","year":"2010","journal-title":"Microb Cell Fact"},{"key":"10.1016\/j.vaccine.2024.03.034_b0290","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.vaccine.2004.11.064","article-title":"A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates","volume":"23","author":"Li","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0295","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)61030-6","article-title":"Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial","volume":"376","author":"Zhu","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.034_b0300","article-title":"Escherichia coli-derived virus-like particles in vaccine development","author":"Huang","year":"201723","journal-title":"npj Vaccin"},{"key":"10.1016\/j.vaccine.2024.03.034_b0305","year":"2024","journal-title":"100 Days"},{"key":"10.1016\/j.vaccine.2024.03.034_b0310","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/14760584.3.2.119","article-title":"Recombivax-HB: perspectives past, present and future","volume":"3","author":"Venters","year":"2004","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.vaccine.2024.03.034_b0315","unstructured":"U.S. Food and Drug Administration. ENGERIX-B. (1989). https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/engerix-b. [accessed 19 December 2023]."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2024.03.034_b0320","first-page":"169","article-title":"Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine","volume":"63","author":"Andr\u00e9","year":"1987","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.vaccine.2024.03.034_b0325","unstructured":"European Medicines Agency. HBVaxPro. (2001). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hbvaxpro. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0330","unstructured":"European Medicines Agency. Fendrix. (2005). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fendrix. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0335","unstructured":"European Medicines Agency. Gardasil. (2006). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gardasil. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0340","unstructured":"European Medicines Agency. Gardasil 9. (2015). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gardasil-9. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0345","unstructured":"U.S. Food and Drug Administration. GARDASIL 9. (2014). https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/gardasil-9. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0350","unstructured":"European Medicines Agency. Mosquirix. (2015). https:\/\/www.ema.europa.eu\/en\/opinion-medicine-use-outside-EU\/human\/mosquirix. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0355","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/hv.6.1.9677","article-title":"From the circumsporozoite protein to the RTSS\/AS candidate vaccine","volume":"6","author":"Cohen","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2024.03.034_b0360","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nbt0988-1065","article-title":"Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of plasmodium falciparum","volume":"6","author":"Rutgers","year":"1988","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0365","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3390\/biom11081072","article-title":"Platforms for production of protein-based vaccines: from classical to next-generation strategies","volume":"11","author":"Cid","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.vaccine.2024.03.034_b0370","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/21645515.2016.1260795","article-title":"Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules","volume":"13","author":"Legastelois","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.03.034_b0375","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/vaccines11071218","article-title":"Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development","volume":"11","author":"Hong","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.034_b0380","doi-asserted-by":"crossref","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","article-title":"Advances and challenges in enveloped virus-like particle (VLP)-based vaccines","volume":"2","author":"Dai","year":"2018","journal-title":"J Immunol Sci"},{"key":"10.1016\/j.vaccine.2024.03.034_b0385","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/glycob\/cws143","article-title":"Impact of a human CMP-sialic acid transporter on recombinant glycoprotein sialylation in glycoengineered insect cells","volume":"23","author":"Mabashi-Asazuma","year":"2013","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2024.03.034_b0390","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/B:GLYC.0000046275.28315.87","article-title":"Comparing N-glycan processing in mammalian cell lines to native and engineered lepidopteran insect cell lines","volume":"21","author":"Tomiya","year":"2004","journal-title":"Glycoconj J"},{"key":"10.1016\/j.vaccine.2024.03.034_b0395","unstructured":"European Medicines Agency. Cervarix. (2007). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cervarix. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0400","unstructured":"U.S. Food and Drug Administration. Cervarix. (2009). https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/cervarix. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0405","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2024.03.034_b0410","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.biologicals.2009.02.014","article-title":"FluBlok, a next generation influenza vaccine manufactured in insect cells","volume":"37","author":"Cox","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2024.03.034_b0415","unstructured":"European Medicines Agency. VidPrevtyn Beta. (2022). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vidprevtyn-beta. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0420","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/vaccines11091420","article-title":"A subunit vaccine candidate composed of Mpox Virus A29L, M1R, A35R, and B6R elicits robust immune response in mice","volume":"11","author":"Yang","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.034_b0425","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/v15071467","article-title":"Mammalian cell-line-expressed CD2v protein of african swine fever virus provides partial protection against the HLJ\/18 strain in the early infection stage","volume":"15","author":"Hua","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.03.034_b0430","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41598-022-26766-y","article-title":"Immunogenicity of a secreted, C-terminally truncated, form of bovine viral diarrhea virus E2 glycoprotein as a potential candidate in subunit vaccine development","volume":"13","author":"Lo","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.03.034_b0435","unstructured":"U.S. Food and Drug Administration. Flucelvax. (2016). https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/flucelvax. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0440","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1586\/14760584.2015.1039520","article-title":"Flucelvax (Optaflu) for seasonal influenza","volume":"14","author":"Manini","year":"2015","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.vaccine.2024.03.034_b0445","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.034_b0450","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.03.034_b0455","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s10616-019-00346-x","article-title":"The transient expression of CHIKV VLP in large stirred tank bioreactors","volume":"71","author":"Chen","year":"2019","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2024.03.034_b0460","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41590-019-0477-z","article-title":"A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection","volume":"20","author":"Slon-Campos","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0465","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3390\/cells10071667","article-title":"Affecting HEK293 cell growth and production performance by modifying the expression of specific genes","volume":"10","author":"Abaandou","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.vaccine.2024.03.034_b0470","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.034_b0475","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40121-023-00792-3","article-title":"Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study","volume":"12","author":"Li","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2024.03.034_b0480","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/oxfordjournals.aje.a120957","article-title":"Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population","volume":"89","author":"Chin","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0485","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0490","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine","volume":"89","author":"Kapikian","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0495","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1128\/jcm.26.8.1595-1597.1988","article-title":"Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity","volume":"26","author":"Murphy","year":"1988","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0500","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b0505","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease","volume":"23","author":"Acosta","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0510","doi-asserted-by":"crossref","first-page":"B209","DOI":"10.1016\/j.vaccine.2012.11.106","article-title":"Strategic priorities for respiratory syncytial virus (RSV) vaccine development","volume":"31","author":"Anderson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0515","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.03.034_b0520","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.03.034_b0525","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.02180-16","article-title":"Immunization with low doses of recombinant postfusion or prefusion respiratory syncytial virus F primes for vaccine-enhanced disease in the cotton rat model independently of the presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant","volume":"91","author":"Schneider-Ohrum","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0530","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2010.00972.x","article-title":"Biological challenges and technological opportunities for respiratory syncytial virus vaccine development","volume":"239","author":"Graham","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2024.03.034_b0535","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.03.034_b0540","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b0545","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/infdis\/jiac327","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F (rsvpref3) candidate vaccine in older adults: phase 1\/2 randomized clinical trial","volume":"227","author":"Leroux-Roels","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.034_b0550","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b0555","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b0560","unstructured":"Fierce Pharma. GSK crushed Pfizer in first round of RSV vaccine showdown; Nov 1, 2023. https:\/\/www.fiercepharma.com\/pharma\/gsks-rsv-vaccine-arexvy-bursts-through-door-blockbuster-sales-within-reach-first-year. [accessed 21\/11\/2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0565","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3390\/v15020439","article-title":"Herpes simplex virus and varicella zoster virus infections in cancer patients","volume":"15","author":"Tayyar","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.03.034_b0570","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0575","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-1702(95)01270-2","article-title":"Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells","volume":"40","author":"Haumont","year":"1996","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2024.03.034_b0580","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10616-021-00468-1","article-title":"Culture media optimization for Chinese hamster ovary cell growth and expression of recombinant varicella-zoster virus glycoprotein E","volume":"73","author":"Kim","year":"2021","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2024.03.034_b0585","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0590","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40266-018-0603-x","article-title":"Recombinant zoster vaccine (shingrix\u00ae): A review in herpes zoster","volume":"35","author":"Syed","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vaccine.2024.03.034_b0595","doi-asserted-by":"crossref","first-page":"1202138","DOI":"10.3389\/fcimb.2023.1202138","article-title":"Human cytomegalovirus in cancer: the mechanism of HCMV-induced carcinogenesis and its therapeutic potential","volume":"13","author":"Yu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0600","doi-asserted-by":"crossref","first-page":"e0285672","DOI":"10.1371\/journal.pone.0285672","article-title":"A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B","volume":"18","author":"Okamoto","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.034_b0605","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1128\/JVI.01251-08","article-title":"Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress","volume":"83","author":"Isaacson","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0610","doi-asserted-by":"crossref","first-page":"e1005227","DOI":"10.1371\/journal.ppat.1005227","article-title":"Crystal structure of the human cytomegalovirus glycoprotein B","volume":"11","author":"Burke","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2024.03.034_b0615","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0620","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.034_b0625","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1086\/315022","article-title":"A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant","volume":"180","author":"Pass Robert","year":"1999","journal-title":"J Infect Dis"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2024.03.034_b0630","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jcv.2009.07.002","article-title":"Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant","volume":"46","author":"Pass","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0635","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/infdis\/jir138","article-title":"Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women","volume":"203","author":"Sabbaj","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.034_b0640","unstructured":"Baudoux GJMFP, Blais N, Marchand M. Novel antigen. Patent number WO2012049317A2; 19 April 2012."},{"key":"10.1016\/j.vaccine.2024.03.034_b0645","unstructured":"Gheysen D. Fusion glycoprotein from HCMV and HSV. Patent number EP0759995A1; 05 March 1997."},{"key":"10.1016\/j.vaccine.2024.03.034_b0650","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-virology-100220-010653","article-title":"Lessons from acquired natural immunity and clinical trials to inform next-generation human cytomegalovirus vaccine development","volume":"9","author":"Hu","year":"2022","journal-title":"Ann Rev Virol."},{"key":"10.1016\/j.vaccine.2024.03.034_b0655","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0660","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/bit.25670","article-title":"Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system","volume":"112","author":"Hofmann","year":"2015","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2024.03.034_b0665","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.2460925","article-title":"The accuracy of reverse transcriptase from HIV-1","volume":"242","author":"Roberts","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.03.034_b0670","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1128\/JVI.72.9.7099-7107.1998","article-title":"Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes","volume":"72","author":"Park","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0675","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1128\/JVI.74.2.627-643.2000","article-title":"A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure","volume":"74","author":"Binley","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0680","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.1128\/JVI.76.17.8875-8889.2002","article-title":"Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1","volume":"76","author":"Sanders","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0685","doi-asserted-by":"crossref","first-page":"e0215106","DOI":"10.1371\/journal.pone.0215106","article-title":"Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells","volume":"14","author":"Cupo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.034_b0690","doi-asserted-by":"crossref","first-page":"e0233866","DOI":"10.1371\/journal.pone.0233866","article-title":"Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: production of HIV envelope proteins as vaccine immunogens","volume":"15","author":"Li","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.034_b0695","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nsmb.3051","article-title":"Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env","volume":"22","author":"Kwon","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101477","article-title":"Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: a first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial","volume":"48","author":"Houser","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0705","doi-asserted-by":"crossref","first-page":"20085","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.03.034_b0710","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","article-title":"Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan","volume":"9","author":"Hsieh","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b0715","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.836745","article-title":"Safety and efficacy of combined intramuscular\/intranasal RAZI-COV PARS vaccine candidate against SARS-CoV-2: a preclinical study in several animal models","volume":"13","author":"Banihashemi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2024.03.034_b0725","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.034_b0730","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","article-title":"Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults","volume":"386","author":"Dai","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b0735","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acschembio.1c00272","article-title":"SARS-CoV-2 RBD-tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies","volume":"16","author":"Valdes-Balbin","year":"2021","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0740","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2022.05.082","article-title":"Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials","volume":"40","author":"Eugenia-Toledo-Roman\u00ed","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2022.100423","article-title":"Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial","volume":"18","author":"Toledo-Roman\u00ed","year":"2023","journal-title":"Lancet Regional Health Americas"},{"key":"10.1016\/j.vaccine.2024.03.034_b0750","article-title":"Structure and computation-guided design of a mutation-integrated trimeric RBD candidate vaccine with broad neutralization against SARS-CoV-2","author":"Liang","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.vaccine.2024.03.034_b0755","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1038\/s41467-022-31379-0","article-title":"Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial","volume":"13","author":"Kaabi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.03.034_b0760","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41392-022-00984-2","article-title":"Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial","volume":"7","author":"Kaabi","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2024.03.034_b0765","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1080\/22221751.2021.1951126","article-title":"Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial","volume":"10","author":"Zhang","year":"2021","journal-title":"Emerging Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.03.034_b0770","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41422-021-00531-8","article-title":"Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2","volume":"31","author":"Sun","year":"2021","journal-title":"Cell Res"},{"key":"10.1016\/j.vaccine.2024.03.034_b0775","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1080\/22221751.2022.2088406","article-title":"Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial","volume":"11","author":"Wang","year":"2022","journal-title":"Emerging Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.03.034_b0780","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41467-021-21634-1","article-title":"S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates","volume":"12","author":"Liang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.03.034_b0785","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.034_b0790","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(22)00055-1","article-title":"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial","volume":"399","author":"Bravo","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.034_b0795","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.766112","article-title":"Preclinical immune response and safety evaluation of the protein subunit vaccine nanocovax for COVID-19","volume":"12","author":"Tran","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0800","article-title":"Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: interim results of a double-blind, randomised controlled phase 1 and 2 trial","volume":"24","author":"Nguyen","year":"2022","journal-title":"Lancet Reg Health Western Pacific"},{"key":"10.1016\/j.vaccine.2024.03.034_b0805","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1080\/22221751.2022.2140608","article-title":"A novel RBD-protein\/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.03.034_b0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI157707","article-title":"A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants","volume":"132","author":"Wang","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2024.03.034_b0815","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s43556-021-00054-z","article-title":"Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA","volume":"2","author":"Liu","year":"2021","journal-title":"Mole Biomed"},{"key":"10.1016\/j.vaccine.2024.03.034_b0820","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1016\/j.vaccine.2021.10.066","article-title":"Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum\/CpG adjuvants","volume":"39","author":"Liu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0825","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1016\/j.vaccine.2021.09.077","article-title":"Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452","volume":"39","author":"Alleva","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0830","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.vaccine.2022.01.043","article-title":"Phase I interim results of a phase I\/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452","volume":"40","author":"Janssen","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0835","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/vaccines10010069","article-title":"Design and immunological properties of the novel subunit virus-like vaccine against SARS-CoV-2","volume":"10","author":"Krasilnikov","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.03.034_b0840","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.vaccine.2022.10.030","article-title":"An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay","volume":"41","author":"Torales","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0845","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbrc.2020.10.012","article-title":"Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies","volume":"538","author":"Yuan","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2024.03.034_b0850","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41541-021-00393-6","article-title":"Scientific rationale for developing potent RBD-based vaccines targeting COVID-19","volume":"6","author":"Kleanthous","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.034_b0855","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/22221751.2022.2056524","article-title":"A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates","volume":"11","author":"An","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.03.034_b0860","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3390\/ijms24021701","article-title":"Recombinant protein vaccines against human betacoronaviruses: strategies, approaches and progress","volume":"24","author":"Kovalenko","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2024.03.034_b0865","first-page":"181","article-title":"Protein subunit vaccine purification. Vaccine development and manufacturing","author":"Yp","year":"2014","journal-title":"Wiley"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2024.03.034_b0870","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jip.2011.05.004","article-title":"Large-scale production and purification of VLP-based vaccines","volume":"107","author":"Vicente","year":"2011","journal-title":"J Invertebr Pathol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0875","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-013-1084-8","article-title":"Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies","volume":"113","author":"Akers","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0880","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0042-6822(91)90496-X","article-title":"Endogenous origin of defective retroviruslike particles from a recombinant Chinese hamster ovary cell line","volume":"181","author":"Anderson","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.03.034_b0885","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.182.4107.56","article-title":"Mammalian cells in culture frequently release type C viruses","volume":"182","author":"Lieber","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.03.034_b0890","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/bit.27200","article-title":"Characterization and mutagenesis of Chinese hamster ovary cells endogenous retroviruses to inactivate viral particle release","volume":"117","author":"Duroy","year":"2020","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2024.03.034_b0895","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1128\/jvi.68.12.7840-7849.1994","article-title":"Chinese hamster ovary cells contain transcriptionally active full-length type C proviruses","volume":"68","author":"Lie","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0900","first-page":"201","article-title":"Recent studies on retrovirus-like particles in Chinese hamster ovary cells","volume":"76","author":"Dinowitz","year":"1992","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2024.03.034_b0905","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1045-1056(03)00065-4","article-title":"Characterisation of endogenous retrovirus in rodent cell lines used for production of biologicals","volume":"31","author":"Shepherd","year":"2003","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2024.03.034_b0910","unstructured":"European Medicines Agency. ICH Guideline Q5A(R2) on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; 2022. https:\/\/www.ema.europa.eu\/en\/ich-guideline-q5ar2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-animal. [accessed 19 December 2023]."},{"key":"10.1016\/j.vaccine.2024.03.034_b0915","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4155\/pbp.14.62","article-title":"Viral clearance for biopharmaceutical downstream processes","volume":"3","author":"Shukla","year":"2015","journal-title":"Pharmaceut Bioprocess"},{"key":"10.1016\/j.vaccine.2024.03.034_b0920","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-61779-921-1_18","article-title":"Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps","volume":"899","author":"Cipriano","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0925","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/bit.10574","article-title":"Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins","volume":"82","author":"Brorson","year":"2003","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2024.03.034_b0930","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1021\/ja908282f","article-title":"Structural characterization of formaldehyde-induced cross-links between amino acids and deoxynucleosides and their oligomers","volume":"132","author":"Lu","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.vaccine.2024.03.034_b0935","first-page":"271","article-title":"Methods of inactivation of highly pathogenic viruses for molecular, serology or vaccine development purposes","volume":"11","author":"Elveborg","year":"2022","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"10.1016\/j.vaccine.2024.03.034_b0940","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.4161\/hv.25602","article-title":"Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice","volume":"9","author":"Raviprakash","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.03.034_b0945","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11157-017-9434-1","article-title":"Cellulose-based virus-retentive filters: a review","volume":"16","author":"Junter","year":"2017","journal-title":"Rev Environ Sci Bio\/technol (Online)"},{"key":"10.1016\/j.vaccine.2024.03.034_b0950","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.memsci.2007.02.045","article-title":"Bioprocess membrane technology","volume":"297","author":"van Reis","year":"2007","journal-title":"J Membr Sci"},{"key":"10.1016\/j.vaccine.2024.03.034_b0955","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s43856-023-00340-7","article-title":"Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells","volume":"3","author":"Alpuche-Lazcano","year":"2023","journal-title":"Commun Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b0960","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00430-014-0374-x","article-title":"Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1\/Pre-S2\/S vaccine","volume":"204","author":"Shouval","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0965","doi-asserted-by":"crossref","first-page":"19255","DOI":"10.18632\/oncotarget.13770","article-title":"Novel Epstein-Barr virus-like particles incorporating gH\/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice","volume":"8","author":"Perez","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.vaccine.2024.03.034_b0970","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12967-015-0415-2","article-title":"A chimeric EBV gp350\/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice","volume":"13","author":"Ogembo","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b0975","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/vaccines8020169","article-title":"A pentavalent epstein-barr virus-like particle vaccine elicits high titers of neutralizing antibodies against epstein-barr virus infection in immunized rabbits","volume":"8","author":"Escalante","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.034_b0980","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1099\/jmm.0.000897","article-title":"Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection","volume":"68","author":"Dong","year":"2019","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.034_b0985","doi-asserted-by":"crossref","first-page":"63488","DOI":"10.18632\/oncotarget.11329","article-title":"Construction and immunological characterization of CD40L or GM-CSF incorporated Hantaan virus like particle","volume":"7","author":"Ying","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.vaccine.2024.03.034_b0990","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1016\/j.vaccine.2010.04.025","article-title":"Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL\/6 mice","volume":"28","author":"Li","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b0995","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1016\/j.vaccine.2019.04.071","article-title":"A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits","volume":"37","author":"Mulama","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b1000","doi-asserted-by":"crossref","first-page":"34481","DOI":"10.18632\/oncotarget.15605","article-title":"BALB\/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH\/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV","volume":"8","author":"Barasa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.vaccine.2024.03.034_b1005","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1016\/j.vaccine.2019.09.057","article-title":"Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies","volume":"37","author":"Buffin","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b1010","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41467-023-37244-y","article-title":"Precise programming of multigene expression stoichiometry in mammalian cells by a modular and programmable transcriptional system","volume":"14","author":"Qin","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.03.034_b1015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.virol.2004.12.036","article-title":"Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein","volume":"333","author":"Purdy","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.03.034_b1020","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1128\/JCM.42.10.4709-4717.2004","article-title":"Noninfectious recombinant antigen for detection of St. Louis encephalitis virus-specific antibodies in serum by enzyme-linked immunosorbent assay","volume":"42","author":"Purdy","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.034_b1025","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2024.03.034_b1030","doi-asserted-by":"crossref","unstructured":"Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife. 2012;1:e00049. 10.7554\/eLife.00049.","DOI":"10.7554\/eLife.00049"},{"key":"10.1016\/j.vaccine.2024.03.034_b1035","article-title":"Hepatitis B virus (HBV) subviral particles as protective vaccines and vaccine platforms","author":"Ho","year":"202012126","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.03.034_b1040","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/0264-410X(94)90155-4","article-title":"Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines","volume":"12","author":"Shouval","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b1045","series-title":"Hepatitis B vaccines in clinical trials","first-page":"83","article-title":"Survey of licensed hepatitis B vaccines and their production processes","author":"Sitrin","year":"1993"},{"key":"10.1016\/j.vaccine.2024.03.034_b1050","doi-asserted-by":"crossref","first-page":"e2128652","DOI":"10.1001\/jamanetworkopen.2021.28652","article-title":"Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial","volume":"4","author":"Vesikari","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.03.034_b1055","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2021.07.034","article-title":"An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity","volume":"39","author":"Fluckiger","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b1060","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3390\/vaccines11111641","article-title":"Gag virus-like particles functionalized with SARS-CoV-2 variants: generation, characterization and recognition by COVID-19 convalescent patients\u2019 sera","volume":"11","author":"Boix-Besora","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.034_b1065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.vaccine.2023.11.048","article-title":"Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components","volume":"42","author":"Gashti","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.034_b1070","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3390\/vaccines10121997","article-title":"Immunogenicity and efficacy of monovalent and bivalent formulations of a virus-like particle vaccine against SARS-CoV-2","volume":"10","author":"Resch","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.034_b1075","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The global landscape of EBV-associated tumors","volume":"9","author":"Shannon-Lowe","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.vaccine.2024.03.034_b1080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","article-title":"Estimating the global burden of Epstein-Barr virus-related cancers","volume":"148","author":"Wong","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.vaccine.2024.03.034_b1085","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.celrep.2013.01.023","article-title":"Human complement receptor type 1\/CD35 is an Epstein-Barr Virus receptor","volume":"3","author":"Ogembo","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2024.03.034_b1090","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2024.03.034_b1095","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/s41598-017-02460-2","article-title":"Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.03.034_b1100","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000067925","article-title":"Review of an inactivated vaccine against hantaviruses","volume":"45","author":"Cho","year":"2002","journal-title":"Intervirology"},{"key":"10.1016\/j.vaccine.2024.03.034_b1105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/(SICI)1096-9071(199608)49:4<333::AID-JMV13>3.0.CO;2-B","article-title":"Immune responses to inactivated vaccine in people naturally infected with hantaviruses","volume":"49","author":"Qunying","year":"1996","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2024.03.034_b1110","doi-asserted-by":"crossref","first-page":"1174030","DOI":"10.3389\/fcimb.2023.1174030","article-title":"Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses","volume":"13","author":"Chen","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.034_b1115","first-page":"406","article-title":"Mechanism of immunopotentiation and safety of aluminum adjuvants","volume":"3","author":"Hogenesch","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.03.034_b1120","series-title":"Oncogenic viruses and mechanism of oncogenesis: study of oncogenic characteristics of HTLV-1 and HHV-8 viruses","first-page":"227","author":"Mayakia","year":"2023"},{"key":"10.1016\/j.vaccine.2024.03.034_b1125","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.034_b1130","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00535-4","article-title":"KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine","volume":"7","author":"Casper","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.034_b1135","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/jssc.201901215","article-title":"Separation of influenza virus-like particles from baculovirus by polymer-grafted anion exchanger","volume":"43","author":"Reiter","year":"2020","journal-title":"J Sep Sci"},{"key":"10.1016\/j.vaccine.2024.03.034_b1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.seppur.2020.116693","article-title":"Baculovirus affinity removal in viral-based bioprocesses","volume":"241","author":"Moleirinho","year":"2020","journal-title":"Sep Purif Technol"},{"key":"10.1016\/j.vaccine.2024.03.034_b1145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chroma.2016.05.053","article-title":"Purification of HIV-1 gag virus-like particles and separation of other extracellular particles","volume":"1455","author":"Steppert","year":"2016","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.vaccine.2024.03.034_b1150","unstructured":"World Health Organization (WHO). Prioritizing diseases for research and development in emergency contexts; 2024. https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-contexts. [accessed 10 January 2024]."},{"key":"10.1016\/j.vaccine.2024.03.034_b1155","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108906","article-title":"Adverse events following COVID-19 vaccination: A systematic review and meta-analysis","volume":"109","author":"Kouhpayeh","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2024.03.034_b1160","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T23:34:27Z","timestamp":1712273667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":232,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24003219"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CHO cells for virus-like particle and subunit vaccine manufacturing","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}